New developments in giant cell arteritis

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Giant cell arteritis (GCA) is a serious medium-to-large vessel vasculitis.
• Recent advancements challenge traditional diagnostic guidelines and understanding of GCA.
• The American College of Rheumatology criteria for GCA diagnosis face scrutiny.

Purpose of the Study:

• To review current understanding of GCA pathogenesis, diagnosis, and treatment.
• To highlight evolving diagnostic approaches and therapeutic strategies for GCA.
• To discuss the relationship between GCA, Takayasu arteritis, and polymyalgia rheumatica.

Main Methods:

• Review of recent literature on GCA pathogenesis, diagnosis, and treatment.
• Analysis of the utility of temporal artery biopsy in current clinical practice.
• Evaluation of emerging diagnostic modalities like positron emission tomography (PET).

Main Results:

• Erythrocyte sedimentation rate (ESR) can be affected by medications (statins, NSAIDs) and hematocrit levels.
• Temporal artery biopsy remains the gold standard for GCA diagnosis, even with shorter lengths or delayed timing post-steroids.
• PET imaging reveals widespread vascular inflammation in GCA, suggesting a broader disease spectrum.

Conclusions:

• GCA, Takayasu arteritis, and polymyalgia rheumatica may represent a disease spectrum rather than distinct entities.
• Interleukin-6 (IL-6) inhibitors show significant promise as a novel therapeutic option for GCA.
• Combined therapies involving corticosteroids and immunosuppressants are crucial for managing GCA.